Live feed08:35:00·8dPRReleasevia QuantisnowAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingByQuantisnow·Wall Street's wire, on your screen.AKTX· Akari Therapeutics plcHealth Care
